Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02128685
Other study ID # UW 13-292
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2016
Est. completion date May 31, 2018

Study information

Verified date October 2018
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine whether the dydrogesterone therapy is associated with reduction in miscarriage in women with first trimester threatened miscarriage. The hypothesis is that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.


Recruitment information / eligibility

Status Completed
Enrollment 406
Est. completion date May 31, 2018
Est. primary completion date May 31, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Age of women from 18-40 years at the time of recruitment (not beyond 40th birthday)

- Absence of fever

- Gestation less than 12 completed weeks as defined by pelvic ultrasound

- Presence of intrauterine gestational sac(s) if an urine pregnancy test is first positive within past 2 weeks

- Presence of intrauterine fetus(es) with crown-rump length of <7mm and no fetal pulsation, or presence of intrauterine fetus(es) with positive fetal heart pulsation confirmed on pelvic scanning

Exclusion Criteria:

- Age of women >40 years at the time of recruitment

- History of recurrent miscarriage defined as at least three consecutive spontaneous miscarriages

- History of known parental chromosomal abnormalities

- Heavy vaginal bleeding requiring surgical intervention

- Severe abdominal pain requiring surgical intervention

- Absence of cardiac pulsation in a fetal pole with crown-rump length of >=7mm on transvaginal scanning

- Use of hCG or progesterone treatment for threatened miscarriage prior to recruitment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dydrogesterone

Placebo


Locations

Country Name City State
Hong Kong Department of Obstetrics and Gynaecology, PYNEH Chai Wan
Hong Kong Department of Obstetrics & Gynaecology, Queen Mary Hospital Hong Kong
Hong Kong Department of Obstetrics & Gynaecology, Kwong Wah Hospital Mong Kok

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary The chance of miscarriage before 20 weeks of gestation At 20 weeks of gestation
Secondary Live birth rate At the time of delivery, from 24 weeks of gestation till term gestation
Secondary The proportion of heavy vaginal bleeding or severe abdominal pain requiring surgical intervention (<20 weeks) Before 20 weeks of gestation
Secondary The incidence of antepartum hemorrhage Any vaginal bleeding during pregnancy from the 24th week gestational age to term From 24 weeks of gestation till term
Secondary The incidence of placenta previa Placenta is being inserted partially or wholly in the lower uterine segment and will be diagnosed by antenatal ultrasound at second and third trimesters From 24 weeks of gestation till term
Secondary The incidence of pregnancy-induced hypertension Any development of newly-onset hypertension (blood pressure persistently >=140/90mmHg on two occasions at least 4 hours apart) during pregnancy after 20 weeks gestation, labour or the puerperium in a previously normotensive non-proteinuric women From 20 weeks of gestation till term
Secondary The incidence of intrauterine death Fetus dies in uterus after 24 weeks gestation After 24 weeks of gestation till term
Secondary The incidence of preterm labour Any premature spontaneous delivery from 24 weeks to 36 weeks gestation From 24 weeks to 36 weeks gestation
Secondary Low birth weight at term (grams) Baby born with birth weight less than 2500g at or after 37 weeks gestation After 37 weeks gestation
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A